Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study

Autor: Fraz A. Ismat, Helen H. Usansky, Raul Villa, Jun Zou, Ariel Teper

Publikováno v: Advances in Therapy.

Treprostinil is a prostacyclin vasodilator widely used for the treatment of pulmonary arterial hypertension (PAH) and, in its inhaled form, for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Treprostinil palmitil inhalatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7538e7281b4b59aad4d2d9e3467b6b7c
https://doi.org/10.1007/s12325-022-02296-x

Estimating Human Drug Oral Absorption Kinetics from Caco-2 Permeability Using an Absorption-Disposition Model: Model Development and Evaluation and Derivation of Analytical Solutions for ka and Fa

Autor: Helen H. Usansky, Patrick J. Sinko

Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 314:391-399

Intestinal transcellular permeability ( P m ), measured across cell lines such as Caco-2 cells in vitro, is often used for assessing oral drug absorption potential in humans. However, the quantitative link between in vitro permeability and apparent i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67a1715f4f51355f6fb908dcd545f31e
https://doi.org/10.1124/jpet.104.076182

[Untitled]

Autor: Helen H. Usansky, Patrick J. Sinko

Publikováno v: Pharmaceutical Research. 20:390-396

Purpose. To explore the possibility of determining in vivo log BB values (the logarithm value of brain to plasma concentration ratio) from in vitro permeability data measured in brain microvessel endothelial cell (BMEC) monolayers.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3e38f3d3833ae75bba3d0ca162e9cb4
https://doi.org/10.1023/a:1022647903205

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.

Autor: Chalmers JD; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. jchalmers@dundee.ac.uk., Usansky H; Insmed Incorporated, Bridgewater, NJ, USA., Rubino CM; Institute for Clinical Pharmacodynamics, Inc, Schenectady, NY, USA., Teper A; Insmed Incorporated, Bridgewater, NJ, USA., Fernandez C; Insmed Incorporated, Bridgewater, NJ, USA., Zou J; Insmed Incorporated, Bridgewater, NJ, USA., Mange KC; Insmed Incorporated, Bridgewater, NJ, USA.

Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2022 Oct; Vol. 61 (10), pp. 1457-1469. Date of Electronic Publication: 2022 Jul 25.

ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.

Autor: Smith RA; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey. roger.smith@asanabio.com., Zammit DJ; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey., Damle NK; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey., Usansky H; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey., Reddy SP; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey., Lin JH; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey., Mistry M; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey., Rao NS; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey., Denis LJ; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey., Gupta S; Asana BioSciences, Princeton Pike Corporate Center, Lawrenceville, New Jersey.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Aug; Vol. 20 (8), pp. 1327-1337. Date of Electronic Publication: 2021 May 27.